Rheumatoid Arthritis: Update Bulletin #3
Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of ulcerative colitis (UC). Topics covered include expert opinions on; Boehringer Ingelheim’s November 2017 announcement that the European Commisssion had granted approval for the company’s adalimumab biosimilar, Cyltezo; the FDA’s acceptance of a regulatory submission for Sandoz’s rituximab biosimilar (GP2013), marketed in Europe as Rixathon/Riximyo since June 2017; and Celltrion’s development of a subcutaneous infliximab biosimilar.
Business Questions:
Business Questions:
- How do KOLs perceive Boehringer Ingelheim’s adalimumab biosimilar, Cyltezo?
- With three adalimumab biosimilars now approved in Europe, what concerns do prescribers have with regard to multiple biosimilar versions becoming available?
- How do KOLs view Sandoz’s Rixathon, the second rituximab biosimilar to enter the RA space in Europe?
- Celltrion is currently developing a subcutaneously administered infliximab biosimilar, but what need is there currently for a subcutaneous version of this product?
- What concerns might prescribers have regarding Celltrion’s subcutaneous infliximab biosimilar?
More Publications
Conference Intelligence Dossier: EASD Annual Meeting 2009
US$ 995.00
October 2009
90 pages
Success in Value Added Services: Delivering Better Patient Outcomes
US$ 695.00
June 2016
-
Market Access Impact (US) [T2DM] (Orals)
US$ 2,575.00
October 2017
-
The Future of Market Access in Europe
US$ 2,245.00
September 2017
-
Renal Cell Carcinoma: KOL Insight
US$ 7,495.00
February 2015
-
